Although these studies are not numerous enough to draw definite conclusions on myostatin inhibition in ALS, these treatments were clearly effective in ameliorating motor symptoms but did not affect symptom onset or survival. This evidence concerns the gene MSTN and amyotrophic lateral sclerosis.